Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Asian Pacific Journal of Allergy and Immunology

Volumn 38, Issue 1, 2020, Pages 1-9

  Prompetchara, Eakachai ^a   Ketloy, Chutitorn ^a   Palaga, Tanapat ^a,b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Coronavirus; Covid 19; Immune evasion; Immune response; Immunopathology

Indexed keywords

ADENOVIRAL VECTOR VACCINE; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL PEPTIDASE IV; DNA VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INACTIVATED VACCINE; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; LIVE VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MRNA VACCINE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS SPIKE PROTEIN; COVID-19; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; AMINO ACID SEQUENCE; ANTIBODY TITER; ANTIGEN PRESENTATION; ASYMPTOMATIC INFECTION; BASIC REPRODUCTION NUMBER; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMMUNICABLE DISEASE; CORONAVIRUS DISEASE 2019; CROSS REACTION; CYTOKINE RESPONSE; CYTOKINE STORM; DIABETES MELLITUS; DISEASE SEVERITY; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INCUBATION TIME; INNATE IMMUNITY; MATHEMATICAL MODEL; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY RATE; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR BINDING DOMAIN; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYMPTOMATOLOGY; VIRAL TROPISM; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS TRANSMISSION; BETACORONAVIRUS; CORONAVIRUS INFECTION; EPIDEMIC; IMMUNOLOGY;

ADAPTIVE IMMUNITY; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; EPIDEMICS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PNEUMONIA, VIRAL; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL VACCINES;

EID: 85082147518     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: 10.12932/AP-200220-0772     Document Type: Review

References (52)

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature [Preprint]. 2020 [cited 2020 Feb 16]: [19 p.]. Available from: https://doi.org/10.1038/ s41586-020-2008-3.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
3. Cyranoski D. Did pangolins spread the China coronavirus to people [Internet]. Heidelberg: Springer Nature; 2020 [cited 2020 Feb 16]. Available from: https://www.nature.com/articles/d41586-020-00364-2
4. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395:514-23.
5. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med [Preprint]. 2020 [cited 2020 Feb 16]: [9 p.]. Available from:https://doi.org/10.1056/NEJMoa2001316
6. Center for Systems Science and Engineering [Internet]. Baltimore: Johns Hopkins; c2020 [cited 2020 Feb 16]. Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE 2020; [about 1 screen]. Available from:https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/b da7594740fd40299423467b48e9ecf6
7. World Health Organization [Internet]. Geneva; World Health Organization; c2020 [cited 2020 Feb 16]. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003; [about 4 screens]. Available from: https://www.who.int/csr/sars/country/table2004 _04_21/en/.
8. World Health Organization [Internet]. Geneva; World Health Organization; c2020 [cited 2020 Feb 16]. Middle East respiratory syndrome coronavirus (MERS-CoV) 2019; [about 4 screens]. Available from: https://www.who. int/emergencies/mers-cov/en/.
9. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med [Preprint]. 2020 [cited 2020 Feb 16]: [2 p.]. Available from: https://www.nejm.org/doi/pdf/10.1056/NEJMc2001468? articleTools=true
10. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A. 2004; 101:6146-51.
11. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25.
12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv [Preprint]. 2020 [cited 2020 Feb 10]: [30 p.]. Available from: http://medrxiv.org/content/ early/2020/02/09/2020.02.06.20020974.abstract
13. World Health Organization holds news conference on coronavirus outbreak - 2/11/2020 [Internet]. New Jersey: CNBC Television; 2020 Feb 11 [cited 2020 Feb 16]. Video:1:12:45 hr. Available from: https://www. youtube.com/watch?v=a0Nu5MUR&feature=youtu.be&t=2166
14. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.
15. Hoffmann M K-WH, Kruger N, Muller M, Drosten C, Pohlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv [Preprint]. 2020 [cited 2020 Feb 16]: [23 p.]. Available from: https://www. biorxiv.org/content/10.1101/2020.01.31.929042v1
16. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA [Preprint]. 2020 [cited 2020 Feb 16]:[2 p.]. Available from: https://jamanetwork.com/ journals/jama/fullarticle/2761659
17. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Weekly. 2020;2:113-22.
18. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet [Preprint]. 2020 [cited 2020 Feb 15]: [9 p.]. Available from: https://doi.org/10.1016/S0 140-6736(20)30260-9
19. Thompson R. Pandemic potential of 2019-nCoV. Lancet Infect Dis [Preprint]. 2020 [cited 2020 Feb 15]: [1 p.]. Available from: https://doi. org/10.1016/S1473-3099(20)30068-2
20. Center for Disease Control and Prevention [Internet]. Atlanta: CDC; c2020 [cited 2020 Feb 10]. Symptoms of Novel Coronavirus (2019-nCoV); [about 1 screen]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/ about/symptoms.html
21. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.
22. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003; 361:1773-8.
23. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13.
24. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95-103.
25. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Preprint]. 2020 [cited 2020 Feb 15]: [15 p.]. Available from: https://doi. org/10.1038/s41586-020-2012-7
26. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382:727-33.
27. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections:implications for SARS. Nat Rev Immunol. 2005;5(12):917-27.
28. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS:recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-34.
29. Channappanavar R, Perlman S. Pathogenic human coronavirus infections:causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529-39.
30. Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016;96:219-43.
31. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386:995-1007.
32. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82-92.
33. Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193:792-5.
34. Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181:5490-500.
35. Shin HS, Kim Y, Kim G, Lee JY, Jeong I, Joh JS, et al. Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection. Clin Infect Dis. 2019;68:984-92.
36. Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, et al. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016;44:1379-91.
37. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291-300.
38. Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J Cell Physiol. 2019;234:2143-51.
39. Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses. J Innate Immun. 2020;12:4-20.
40. Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One. 2014;9:e88716.
41. Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, et al. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein. Sci Rep. 2017;7:44875.
42. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226-36.
43. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25:2832-8.
44. Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine -Preliminary Report. N Engl J Med [Preprint]. 2017[cited 2020 Feb 10]:[16 p.]. Available from: https://doi.org/10.1056/ NEJMoa1708120
45. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-79.
46. Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019;27:757-72.
47. Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319-34.
48. Koch S, Pong W, Editors. The count of companies developing vaccines for coronavirus rises 2020 [Internet]. Redwood: BioCentury; 2020 [cited 2020 Feb 16]. Available from: https://www.biocentury.com/article/304412
49. Thomas SJ, L’Azou M, Barrett AD, Jackson NA. Fast-Track Zika Vaccine Development - Is It Possible? N Engl J Med. 2016;375:1212-6.
50. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019;11.
51. Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome -Coronavirus. Front Microbiol. 2019;10:1781.
52. Schindewolf C, Menachery VD. Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Viruses. 2019;11.